AKT1 and gastric cancer: Overall, this study revealed that LINC01559 promoted GC progression through upregulation of PGK1 and downregulation of PTEN to activate the PI3K/AKT pathway, suggesting that LINC01559 could be a therapeutic target in GC (69).